hotspot -WSS

hotspot

author：Wikipedia 2025-09-03 12:02:32 - browse：9

This is the inaugural edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.

Hello! Welcome to the premiere issue of Adam’s Biotech Scorecard. I’m excited to get started. Let’s do this! (By the way, the AF in the logo are my initials, not the “other” AF.)

The contrarian view of Viking Therapeutics

Closeup financial chart

The developer of a dual-acting GLP-1/GIP treatment for obesity is riding high on positive data and takeout speculation. The drug, called VK2735, has shown impressive weight loss with minimal gastrointestinal side effects in both subcutaneous and oral formulations, positioning it as a strong challenger to the obesity juggernauts from Eli Lilly and Novo Nordisk. With a stock price that has soared nearly 800% over the past year, Viking is now a $9 billion company and a prime acquisition target for a cash-rich pharma company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： New CMS data security rules will hurt Medicare, Medicaid research

hotspot

WSS

Readout Newsletter: BridgeBio, Akero, and human embryo models

The public health thinking behind the CDC’s new Covid guidance

Secretariat’s lessons for human medicine

Microsoft's Peter Lee: Generative AI could help doctors be more human

Medicare drug price negotiation continues, as pharma counteroffers

Harvard's David Sinclair gets blowback over aging

focus

hotspot

The contrarian view of Viking Therapeutics

hotspot

Medical leaders decry Supreme Court decision on affirmative action

Microsoft's Peter Lee: Generative AI could help doctors be more human

Affirmative action in medical school literally saved lives

Surprise medical billing ban raises prices elsewhere

What does generative AI mean for health care? We asked experts

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Secretariat’s lessons for human medicine

In Memoriam: Notable people who died in 2023

Abridge raises $150m as clinical notes automation market heats up

entertainment

Surprise medical billing ban raises prices elsewhere

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Surprise medical billing ban raises prices elsewhere

Pregnant women don't need prenatal multivitamins, study concludes

Abridge raises $150m as clinical notes automation market heats up

First over

hotspot

explore

focus

hotspot